Investigational pharmacological agents for the treatment of ARDS.
Katyayini AribindiMichelle LimSatyan LakshminrusimhaTimothy E AlbertsonPublished in: Expert opinion on investigational drugs (2024)
Although ALI/ARDS modifying pharmacological agents have been identified in COVID-related disease, the data in non-COVID ALI/ARDS has been less compelling. The increased use of more specific molecular phenotyping based on physiologic parameters and biomarkers, will ensure equipoise between groups, and will likely allow more precision in confirming pharmacological agent efficacy in future studies.
Keyphrases
- acute respiratory distress syndrome
- coronavirus disease
- sars cov
- extracorporeal membrane oxygenation
- mechanical ventilation
- high throughput
- electronic health record
- respiratory syndrome coronavirus
- randomized controlled trial
- intensive care unit
- clinical trial
- machine learning
- current status
- big data
- combination therapy
- phase ii
- artificial intelligence